M.D., CEO, OncoHost
Biography
Dr. Ofer Sharon is a physician and entrepreneur with over 17 years of experience in the oncology drug development industry. Sharon is dedicated to overcoming one of the major obstacles in clinical oncology today – resistance to therapy and his team at OncoHost develop personalized strategies to maximize the success of cancer therapy by identifying host-driven pro-tumorigenic biological processes associated with therapy resistance and tumor spread. Sharon and his team are developing the first of-its-kind proteomic profiling platform for the early prediction of cancer treatment responsiveness in patients, as well as for the discovery of new targets to overcome treatment resistance. Sharon previously served as a Chief Medical Officer and New Technologies Scout in companies such as Roche, Merck and AstraZeneca, and co-founded several healthcare companies.
Clinical Dx Showcase:
OncoHost
OncoHost is the global leader in host response profiling, developing personalized strategies to maximize the success of cancer therapy. OncoHost utilizes proprietary proteomic analysis, enabling personalized oncological treatment strategies with improved outcomes and reduced side effects.
Host Response Profiling for Immunotherapy Response Prediction
A major obstacle in clinical oncology is resistance to therapy. Host response profiling and proprietary proteomic analysis improves our understanding of how cancer treatment can influence tumor progression, better identifying which treatments or drug combinations may result in improved outcomes.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
